Compression of veterinary tablet formulations containing hydroxybenzoate ester preservatives requires pre-milling to D90 < 150 µm because untreated methyl hydroxybenzoate plate-like crystals with D50 between 200 µm and 400 µm segregate in hopper screw feeds and raise die-fill variation above 3.0% on rotary presses. In chewable companion animal tablets with liver hydrolysate at 8–12% w/w and sorbitol at 15–20% w/w, the hygroscopic excipient fraction generates local water activity above 0.75 after decompression even though bulk moisture content is below 3.0% Karl Fischer. Methyl hydroxybenzoate at 0.05–0.10% w/w combined with propyl hydroxybenzoate at 0.01–0.03% w/w is preblended with the filler phase before addition of starch paste binder to inhibit Aspergillus niger and Penicillium verrucosum germination during wet mass holding times up to 45 minutes. The sodium salts of the esters can be dissolved in the aqueous binder at 20–25% w/w, but the resulting binder solution pH should be maintained at 6.5–7.2 to limit alkaline hydrolysis to p-hydroxybenzoic acid, which is pharmacologically inactive as a preservative and may reduce finished tablet hardness. Drying in a fluid-bed unit with inlet air at 55–65 °C and product temperature 38–42 °C prevents ester sublimation; methyl ester loss becomes measurable above 70 °C. Compaction with a rotary tablet press at 10.0–25.0 kN main compression force and 30 rpm for concave bevel-edged tooling produces tablet cores of 2.5–3.0 mm thickness without punch filming. Finished tablets are tested according to USP 61 and USP 62, with total aerobic microbial count ≤10³ CFU/g and absence of Escherichia coli. These conditions apply to chewable dewormer tablets, urinary acidifier tablets, and multi-vitamin boluses for companion animals.

Why Do Multidose Veterinary Injections Require Ester Hydrolysis Profiling Prior to Terminal Sterilisation?

Multidose veterinary injections preserved with hydroxybenzoate esters require terminal sterilisation F0 ≥ 8 at 121 °C, but the ester blend is not inert under all process conditions. Methyl hydroxybenzoate at 0.065–0.15% w/v and propyl hydroxybenzoate at 0.015–0.05% w/v in aqueous vehicles adjusted to pH 4.5–6.0 with citrate or acetate buffer retain more than 95% of declared ester content after 15 minutes at 121 °C, whereas the same blend at pH 7.8 shows hydrolysis to p-hydroxybenzoic acid above 10–15% and a measurable fall in preservative efficacy. Aqueous solubility at 25 °C for methyl, ethyl, propyl and butyl esters is approximately 2.5 g/L, 1.7 g/L, 0.5 g/L and 0.2 g/L respectively; therefore injection vehicles commonly include propylene glycol 10–30% v/v to maintain solution clarity at 2–8 °C storage. Polysorbate 80 at 0.1–0.5% w/v sequesters a fraction of the ester within micelles, so free antimicrobial concentration must be measured by equilibrium dialysis or HPLC after sterile filtration, not by total content alone. Silicone tubing and butyl rubber stoppers adsorb propyl ester more strongly than methyl ester; pre-soaking closures in autoclaved vehicle for 12 hours reduces batch-to-batch loss variation from 5–8% to 1–2%. Multidose oxytocin solutions and vitamin B-complex veterinary injectables preserved with 0.1% w/v methyl plus 0.02% w/v propyl hydroxybenzoate remain within Ph. Eur. 5.1.3 acceptance after 4-week challenge when stored below 25 °C. Not for intrathecal or epidural administration.

Preservative Partitioning in Hard Gelatin Capsule Powders and Shell Moisture Gradients

For hard gelatin capsule formulations, the ester's log P determines partition between the anhydrous fill powder and the shell moisture layer. Methyl hydroxybenzoate with log P 1.96 stays predominantly in the fill matrix at shell relative humidity 45–55%, while propyl hydroxybenzoate log P 3.04 migrates into the gelatin wall and can reduce free fill concentration by as much as 15–20% over six months at 30 °C/65% RH. Capsule powders composed of spray-dried lactose, maize starch and magnesium stearate should be preblended with microfine methyl hydroxybenzoate at 0.08–0.12% w/w using geometric dilution in a bin blender at 10 rpm for 15 minutes; addition of the preservative after lubricant blending produces uneven distribution and localised concentrations above 0.25% w/w that can soften the gelatin shell. Fill weight uniformity on a tamping pin capsule machine is maintained within ±3% when the powder mix bulk density is held at 0.55–0.70 g/mL and the tamping pins are set to 8–10 mm penetration. Finished capsules stored in PVC/PVDC blisters with moisture vapour transmission rate below 0.5 g/m²/day show no visible fungal colonies on Sabouraud dextrose agar after 28 days at 25 °C/75% RH. Companion animal cefalexin capsules and canine joint supplement capsules containing methyl hydroxybenzoate at 0.10% w/w comply with Ph. Eur. 5.1.4 non-sterile product limits.

Dry veterinary oral powders intended for reconstitution in drinking water are essentially anhydrous, with water activity below 0.45, so the hydroxybenzoate ester does not act as a dry-state preservative but as a dissolved-state preservative reservoir after the flock is placed in water. A blend of methyl hydroxybenzoate 0.05–0.08% w/w and ethyl hydroxybenzoate 0.02–0.04% w/w in a glucose-anhydrous carrier dissolves within 60–90 seconds in water at 25 °C when the ester particles are jet-milled to D90 below 100 µm; larger particles above 250 µm remain undissolved for more than 5 minutes and contribute to blocked drinker lines on poultry farms. The sodium salt of methyl hydroxybenzoate at 0.06–0.12% w/w is preferred for water-soluble antibiotic and electrolyte powders because it dissolves rapidly at pH 7.0–7.8, whereas the free acid form requires pH below 5.0 for complete dissolution. Blending in a ribbon mixer at 20 rpm for 12 minutes with a 1:10 staged preblend avoids content uniformity failures; final blend RSD should remain below 5.0% as determined by HPLC. In field-use conditions, reconstituted solutions at 10 g powder per litre water maintain preservative efficacy for 24 hours at ambient temperatures up to 30 °C, but water containing high bicarbonate hardness above 300 ppm as CaCO₃ can increase pH above 8.0 and accelerate ester hydrolysis. Water-soluble tetracycline and vitamin-electrolyte powders packed in low-density polyethylene sachets with moisture barrier below 0.3 g/m²/day retain less than 0.5% moisture after 24 months at 25 °C/60% RH.

When Wet Granulation Overrides Direct Compression for Veterinary Granule Premixes

When wet granulation becomes necessary because the veterinary granule formulation contains a high dose of hygroscopic liver extract or molasses at 10–15% w/w, hydroxybenzoate ester preservation is integrated into the binder phase rather than the dry powder phase. A binder solution containing 5% w/w hydroxypropyl methylcellulose, 20% v/v ethanol and 0.08–0.12% w/w methyl hydroxybenzoate plus 0.02–0.04% w/w propyl hydroxybenzoate is sprayed onto a lactose and maize starch granule bed in a top-spray fluid-bed granulator at inlet air temperature 55–65 °C and product temperature 38–42 °C. Ethanol at 20% v/v is required because the free acid esters have water solubility below 0.3% w/v, and direct addition of dry crystals to the granule bed produces localised preservative inclusions visible as white specks with content deviating by more than 20% from label claim. The sodium salts of methyl and propyl esters can be dissolved in pure water at 5–10% w/v if ethanol-free granulation is required for solvent-residue compliance, but the binder pH must be held at 6.5–7.0 to minimise hydrolysis; residual p-hydroxybenzoic acid should not exceed 0.5% of the ester mass. Drying endpoint is based on granule moisture by Karl Fischer, typically 2.0–2.5% w/w for oral suspension granules, and the dry granules are passed through a 1.00 mm sieve to remove oversize agglomerates before blending with preservative-free flavour premix. Reconstituted suspensions at 25 mg/mL in water at 25 °C reach homogeneity within 60 seconds and retain more than 90% preservative potency after 8 hours when stored below 25 °C.

Maintain a 4:1 Methyl-to-Propyl Ester Ratio in Mineral Feed Premix Blending

Maintain a 4:1 methyl-to-propyl hydroxybenzoate ester ratio in dry mineral feed premixes when ground limestone or calcium carbonate carriers exceed 15% w/w of the formulation. The methyl ester provides aqueous-phase antifungal activity against Fusarium and Aspergillus species in moisture pockets formed during storage, while the propyl ester partitions into lipid-rich ingredients such as rice bran and soybean meal. Total ester input is 0.05–0.20% w/w of the premix; above 0.25% w/w, calcium carbonate particles become coated with hydrophobic ester and the mixture can develop poor flow, with angle of repose rising above 45° and bridging in silo discharge. Ester powders are preblended with silica dioxide at 1:5 ratio and then passed through a 250 µm screen before addition to the ribbon mixer. The carrier moisture content must be below 10% w/w and water activity below 0.65, because alkaline earth carbonates in the presence of free moisture above pH 8.5 promote hydrolysis of the ester to p-hydroxybenzoic acid, which lacks antifungal potency. Ribbon mixing at 15 rpm for 12 minutes after the ester preblend addition achieves coefficient of variation below 5.0% in 1 kg samples, but extended mixing beyond 30 minutes causes electrostatic adhesion of ester particles to the mixer walls. Shelf-life testing at 30 °C/75% RH in woven polypropylene bags with inner polyethylene liner shows total fungal count below 10² CFU/g for 12 months when the premix is formulated at 0.12% w/w total ester and initial moisture is below 8% w/w.

What Concentration Boundaries Prevent Re-Crystallisation in Co-Solvent Veterinary Oral Solutions?

For aqueous oral vehicles containing propylene glycol at 10–20% v/v, methyl hydroxybenzoate remains in solution at 0.08–0.15% w/v at 25 °C, but propyl hydroxybenzoate at 0.03–0.05% w/v precipitates as needle-like crystals when the solution is stored at 2–8 °C for more than 48 hours. The critical boundary is approximately 0.04% w/v for propyl ester at 10% v/v propylene glycol; raising propylene glycol to 30% v/v extends the boundary to 0.06% w/v but increases viscosity beyond 5.0 mPa·s and may reduce voluntary intake in swine. Ethanol at 10–15% v/v can replace propylene glycol for poultry oral solutions, but at ethanol concentrations above 20% v/v, the ester contribution to preservation becomes difficult to separate from the solvent-associated antimicrobial effect. A stable oral solution for cattle and swine is formulated with methyl hydroxybenzoate 0.10% w/v, propyl hydroxybenzoate 0.02% w/v, propylene glycol 15% v/v, glycerol 10% v/v and citrate buffer at pH 5.0–6.0. The solution is filled into amber PET bottles with desiccant-containing closures and shows no visible crystallisation after three freeze-thaw cycles between -5 °C and 40 °C. Preservative efficacy testing according to Ph. Eur. 5.1.3 and USP 51 is performed on each batch because minor variations in polysorbate 80, if present at 0.1% w/v, reduce free ester concentration below the minimum inhibitory concentration for Pseudomonas aeruginosa.